About

We are focused on the industries of food and beverages, nutritional supplements, cosmetics, medical devices and pharmaceuticals. We provide full legal services for the lifecycle of products aimed at improving the population’s health and wellness.

Amin Talati Wasserman has gained a strong reputation for its work at the cutting edge of food, drug (FDA), advertising (FTC) and intellectual property (IP) laws, responding nimbly to rapid changes in the regulatory climate and market place. We work with some of the most innovative products in this sphere, such as raw juices, allergy-free foods, botanical drugs, cosmeceuticals and hemp products. We counsel on regulatory compliance and risk-analysis, product development, as well as on trademark and patent protection.

In addition to guiding our clients through the strategic development of new products through regulatory approvals to the marketplace, we advise on all post-launch processes as well to ensure labeling, advertising, safety and manufacturing compliance requirements. We counsel on recalls, consumer false advertising class actions, trademark and patent infringement disputes, FDA, FTC and State AG government investigations, commercial (breach of contract) litigation, unfair competition, Proposition 65, National Advertising Division and Consumer Product Safety Commission matters. We also provide IP and compliance due diligence assessments in mergers/acquisitions and guide companies on IP freedom-to-operate opinions.

What Our Clients Say

"Their strength is their knowledge of the regulatory and legal hurdles and for finding the best regulatory fit for a product concept. They know the health care industry leaders and the agencies that regulate them. 

This firm excels at facilitating interactions with government regulatory and industry's self regulating bodies."

– CEO of Major Pharmaceutical Company

Evan Phelps To Present Webinar On Breakthrough Medical Devices

Monday, Nov. 16, 2020 • 1:30 p.m. – 3:00 p.m. EST In the past, it’s been difficult to get marketing authorization from the FDA for novel medical device technologies — and even if those authorizations were made, it could take years for a Centers for Medicare and Medicaid Services (CMS) coverage decision. Not anymore. With […]

see all news >